X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Sun Pharma: Caraco effect visible - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Sun Pharma: Caraco effect visible

Nov 4, 2004

Performance Summary
Sun Pharmaceutical declared its 2QFY05 results recently. The topline of the company grew by 10% while the growth in bottomline was 29% on a YoY basis. The improvement in bottomline was mainly due to a huge 490 basis points improvement in its operating profit margin in 2QFY05, on the back of savings made in raw material costs and other expenditure.

(Rs m) 2QFY04 2QFY04 % Change 2QFY04 2QFY04 % Change
Net sales 2,833 3,122 10.2% 5,273 6315 19.8%
Total Expenditure 1,915 1,955 2.1% 3,524 4,129 17.2%
Opearting profit 919 1,167 27.0% 1,749 2,185.2 24.9%
Operating Profit margin(%) 32.4% 37.4%   33.2% 34.6%  
Other Income 48 24 -49.0% 91 68 -25.4%
Interest 18 5 -73.9% 38 11 -71.1%
Depreciation 63 86 38.1% 127 166 30.8%
Profit before tax 887 1,101 24.1% 1,674 2,076 24.0%
Tax 57 31 -46.8% 104 68 -34.3%
Profit after tax 829 1,070 29.0% 1,571 2,007.5 27.8%
Profit after tax margin (%) 29.3% 34.3%   29.8% 31.8%  
Minority interest 127 39 -69.6% 231 92 -60.1%
Net profit 702 1031 46.9% 1,339 1,915 43.0%
No. of shares 186 186   186 186  
Earning per share* 15 22   14 21  
P/E ratio         22.4  
(*annualised)            

Company's background
Sun Pharma is a leading domestic pharma company with a strong presence in the lifestyle therapeutic segment. However, it started focusing in the exports market and in FY02 it acquired Caraco Pharma in the US. Further, it increased its stake in Caraco pharma in FY04 to 61% taking over majority control. With the help of its US subsidiary, the company has been able to grow its US business, which brings in synergies with Sun's business by backward integration in both manufacturing and R&D.

What has driven performance in 2QFY05?
Sales: Sun Pharma’s topline growth was fuelled by a strong performance in its formulations business, which recorded a 15% growth during 2QFY05. In the first half of FY05 the sales growth was 21% in formulations exports, which basically grew due to strong growth shown by Sun pharma's US based subsidiary Caraco Pharma. Caraco Pharma has shown a growth of 50% in the topline in the September quarter. However, revenues from the bulk drugs segment have slipped marginally due to the company's focus on formulations business. Sun Pharma’s core therapeutic segments of psychiatry, neurology, cardiology, diabetology, and gastroenterology, which make up for 70% of the domestic formulations sales, grew by about 12% as a whole during the quarter.

Sales Break-up
(Rs m) 2QFY04 2QFY05 %Change 1HFY03 1HFY04 %Change
Domestic            
Formulations 1,563 1,725 10.4% 2,854 3,504 22.8%
Bulk 297 290 -2.4% 554 551 -0.5%
Others - 19 - - 30 -
Total (A) 1,860 2,034 9.3% 3,408 4,085 19.9%
Exports            
Formulations 743 862 16.0% 1,392 1,687 21.2%
Bulk 230 226 -1.5% 473 543 14.9%
Total (B) 973 1,088 11.8% 1,865 2,230 19.6%
Grand Total ((A)+(B)) 2,833 3,122 10.2% 5,273 6,315 19.8%

Operating margin: The operating margin of the company expanded by 490 basis points basically due to increased contribution from the exports business. With the company transferring Caraco pharma's manufacturing activities to the Indian plants, the company has been able to expand margins further. Despite a huge surge in R&D expenditure (8.2% of sales in 2QFY05), company managed to increase its operating profit due the savings in raw material costs and other expenditures.

Net Profit: The profit after tax has risen by 29% and the net profit margin expanded by 500 basis points. The major contribution to this expansion comes from improvement in its operating performance, however, lower tax charges due to increasing contribution from exports has also helped the cause.

What to expect?
At 462 the stock is trading at a P/E ratio of 22.4 times its annaulised 1HFY05 earnings. With its US subsidiary now turning profitable, the company is in a position to leverage its cost advantage in manufacturing and R&D by launching new drugs through Caraco Pharma in the US markets. Also, being a dominant player in the lifestyle segment in the domestic market, the company might see a good growth rate going forward as these segment are amongst the fastest growing therapeutic segments in the domestic market.


Equitymaster requests your view! Post a comment on "Sun Pharma: Caraco effect visible ". Click here!

  

More Views on News

SUN PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 265.5% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, SUN PHARMA has posted a net profit of Rs 15 bn (up 265.5% YoY). Sales on the other hand came in at Rs 77 bn (up 16.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 20, 2018 | Updated on Dec 20, 2018

Here's an analysis of the annual report of SUN PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 110.7% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, SUN PHARMA has posted a net profit of Rs 1 bn (down 110.7% YoY). Sales on the other hand came in at Rs 69 bn (up 4.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

More Views on News

Most Popular

Stocks that Could Be Out of Reach Post Elections(The 5 Minute Wrapup)

Apr 9, 2019

It's a matter of time before the stocks catch the fancy of the markets and big investors.

3 Indian Stocks with Amazon-Like Potential(Profit Hunter)

Apr 10, 2019

We have identified 3 stocks with huge wealth building potential which meet our 'Click of a Button' criteria.

This Company is Making a Big Comeback and You Can Now Profit from Its Example(The 5 Minute Wrapup)

Apr 10, 2019

How Dell got its mojo back.

This is Why the Stock of Jubilant FoodWorks Went Up 1,160%(The 5 Minute Wrapup)

Apr 12, 2019

This critical business strategy has enabled companies to scale their operations faster.

Pocketing Massive Gains with HDFC And HDFC Bank(Profit Hunter)

Apr 12, 2019

Here's how one could have generated gains of Rs 59,250 in 10 days by trading HDFC and HDFC Bank with a capital of Rs 4 lakh.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Apr 18, 2019 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA 8-QTR ANALYSIS

COMPARE SUN PHARMA WITH

MARKET STATS